Text Size
YouCMSAndBlog Module Generator Wizard Plugin



PWRM Is Today's Low Float Subpenny Biotech Play







Company: Power3 Medical Products, Inc.

Symbol: PWRM.ob

Current PPS: $0.0051 (Near the All Time Low PPS Solid Support Level Minimal Risk)

Outstanding Shares: 571.6M

Float: 446M (Low Float Just How We Like)

10 Day Avg. Volume: 698.9K

Website: www.Power3Medical.com

Power3 Medical Products Inc. (PWRM.ob) is a is a biotechnology company focused on the development and marketing of diagnostic products through the analysis of proteins. Founded in 1992 with a corporate headquarters in Texas PWRM's goal is to become the leading biotech company specializing in the commercialization of proteomics Intellectual Property (IP) for the diagnosis and treatment of diseases such as Alzheimer's (AD), Breast Cancer, Lou Gehrig’s disease/ALS (amyotrophic lateral sclerosis) and Parkinson’s disease. Through the use of innovative technologies, state of the art quality procedures, and advanced research methodologies PWRM strives to find the answers to the development of these neurodegenerative and neuromuscular diseases that affect millions of people around the world.

Some bullet point facts regarding the global impact of these diseases:

  • 1 our of 8 women world wide are affected by some form of breast cancer.
  • 7-10 million people are currently living with Parkinson's disease throughout the world.
  • Out 100,000 people worldwide, 1-3 will develop ALS
  • Alzheimer's globally affects over 35 million people.

As you can seen these diseases have reached global epidemic numbers are continuing to rise. PWRM sees the need to pinpoint the cause of these deadly diseases.

How is this done?

PWRM and their team of scientists focus on proteomics which is the study and analysis of proteins. By studying proteins PWRM's scientists are able learn more about the functioning of a healthy body and identify what proteins are associated with certain diseases. The fact that proteins are considered the building blocks of life makes them an important piece of the puzzle in finding the cause and early detection of these serious diseases that have plagued us for so long. 

With a combined 50 plus years of proteomic experience, PWRM has identified 334 protein biomarkers. These patent-pending biomarkers overcome critical obstacles facing pharmaceutical and diagnostic companies and are currently being used to design tests to diagnose diseases and discover targets for new drugs to treat the diseases. As of now PWRM has two diagnostic tests to encourage the early detection of breast cancer (BC-SeraPro™) and Alzheimer's, and Lou Gehrig's disease (NuroPro™).

PWRM's IP (Intellectual Property) Huge Profit Potential

Through their independent and collaborative research, PWRM is continually building its portfolio of intellectual property. PWRM's IP can then be licensed to pharmaceutical companies to be used in their $300 billion market to develop new drugs , diagnostic test manufacturers, and other biotech companies for the development of commercial applications for the treatment of the following:

  • Breast Cancer
  • Alzheimer's Disease
  • ALS (Lou Gehrig's Disease)
  • Parkinson's Disease
  • Chemotherapeutic Drug Resistance
  • Gastrointestinal Disease
  • Metabolic Syndrome
  • Drug Targeting

As of now the world clinical diagnostic market is worth over $70 billion. New diagnostic test development is predicted to provide the 1st big revenue contributions based upon proteomic analysis. PWRM is able to quickly and accurately identify patterns of proteins associated with disease and apply them to screening diagnostic and drug targets. Once their findings are validated through clinical trials, PWRM benefits financially from investing partnerships or licensing arrangements for these protein biomarkers and their applications. PWRM's revenue then filters in the form of upfront payments, licensing fees, milestone payments and royalties. Each validated biomarker, pattern, new diagnostic test, or drug target, may have a potential market value of $10-100 million.

Spending for disease treatment has never been a rampant as it is today. The cost of Alzheimer's Disease continues to rise at record pace as the number of known cases keeps on growing. By 2050 the cost for A.D. treatment will reach the $1 trillion mark. With the help of PWRM's early detection tests spending could be greatly reduced in the future.

Potential for Huge Profits In a Growing Market

PWRM specializes in the field of Proteomics. The Proteomics market is a rapidly emerging field on the heals of DNA sequencing, which provides a better understanding of the formation of human diseases. The Proteomic market is expected to grow at a 20% CAGR (Compound Annual Growth Rate) between 2011-2013 as this scientific method is being adapted on a global scale. PWRM has the first-mover advantage over other biotech companies who have failed to see the profit potential that Proteomics offer.

As you can see from the chart below PWRM is trading near its all time low PPS. At $0.0051 PWRM is a subpenny stock, as we know subpenny stocks have a tendency to move fast and have the potential for huge gains in a short amount of time. About a month ago PWRM was trading at around the same PPS and saw a nice bounce upwards for a +25% gain. 

With its low float of 446 million and breaking news rumored to be released.. we could see gains that dwarf that amount today!!!

We are urging all members to keep a close eye on PWRM and to be ready to pick up some shares early today at 9:30am EST.

Power3 Medical's Goldknopf to Deliver Keynote in Beijing

HOUSTON, TX--(Marketwire -09/14/11)- Power3 Medical Products, Inc. (OTC.BB: PWRM.OB - News), a biotechnology company, announced today that President and Chief Scientific Officer Dr. Ira L. Goldknopf will deliver a keynote address to the International Congress and Exposition of Molecular Diagnostics in Beijing, China, September 22, 2011.

"A panel of diagnostic leaders selected Dr. Goldknopf for the Keynote Forum opening the meeting. His talk, 'Navigating the Waters of Omic Medicine for Alzheimer's Disease,'" said Helen R. Park, MS, CEO of Power3, "addresses key obstacles." Also, Dr. Goldknopf will chair a session: Diagnostic Biomarkers for CNS Diseases and Genetic Disorders.

Power3 has patents pending, an exclusive license from Baylor College of Medicine, has delivered 9 presentations at international scientific meetings, and published 6 articles in scientific journals on NuroPro®.

Power3 Medical Products
Power3 Medical Products, Inc. a leading bio-technology company develops innovative diagnostic tests in neurodegenerative diseases (NuroPro®): Alzheimer's disease, Parkinson's disease and ALS (Lou Gehrig's disease) and cancer (BC-SeraPro™), discovers protein biomarkers and tests to detect disease, progression, drug response, and disease mechanisms.







Enhanced by Zemanta

FREE Stock Alerts


Partner Sites

Follow Us On

As Seen On...



Yahoo Finance

Google Finance


Penny Stock Picks